Why Gilead Sciences bets on Sunlenca as a long-acting HIV anchor
How the long-acting
dosing works. In practice, Sunlenca therapy starts with an oral lead-in and
loading doses, after ... |
Misinformation threatens rollout of HIV prevention drug lenacapavir
Health experts say false claims about the lenacapavir injection could undermine efforts to reduce new HIV infections in South Africa. View article...